Session: MON 238-262-Vitamin D Action, Deficiency & Disorders
Bench to Bedside
Poster Board MON-256
Methods: This chart review gathered clinical information from 376 subjects seen in the Osteoporosis Program at Women’s College Hospital who were found to be vitamin D deficient (<50 nmol/L) or insufficient (50-74 nmol/L) and underwent treatment with the Vitamin D Protocol. This protocol outlined a specific algorithm for physicians to replace vitamin D. Patients were instructed to repeat blood work in 6 months. Patient with the following medical comorbidities were excluded: renal failure, hypercalcemia, hypercalciuria, renal calculi and teriparatide therapy.
Results: 376 charts were reviewed and of the 325 eligible subjects, 169 (52%) completed post-protocol blood work. The mean increase in vitamin D after treatment was 23.0 +/- 31.1 nmol/L. 56% of subjects achieved the target Vitamin D level of 75 nmol/L or greater following the protocol. Patients with a post-protocol vitamin D level <75 nmol/L were more likely to have a malabsoprtion syndrome (18.9% vs 7.4%, p=0.02) and took longer to complete their post protocol bloodwork (9.3 vs 7.9 months, p=0.002). Other demographic and clinical factors such as gender, age, BMI, baseline BMD and history of fragility fracture were similar in both groups. 28 patients in the group which did not achieve target had in fact a lower vitamin D level after the protocol than baseline.
Conclusion:This is the first protocol for vitamin D supplementation to be studied and demonstrates a significant improvement in vitamin D levels by nearly 50%. Compliance in our study was low with 52% of patients completing blood work. While only 56% of patients achieved the target vitamin D level, there is likely a large component of laboratory variability in testing results, given that 17% of patients had a lower vitamin D level following treatment with the protocol.
Disclosure: SJ: Speaker, Bristol-Myers Squibb, Speaker, Shire, Consultant, Genzyme Corporation, Advisory Group Member, Warner Chilcott, Advisory Group Member, Novartis Pharmaceuticals, Advisory Group Member, Amgen, Speaker, Sanofi, Consultant, Cytochroma. Nothing to Disclose: VS, SAK, IR
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters